KEY TAKEAWAYS
- The study aimed to investigate the increased incidence of BCR::ABL1 p190+ in pts with AML and its clinical implications.
- Researchers noticed a higher frequency of BCR::ABL1 p190+ in pts with AML cohort compared to global rates; further investigation is ongoing.
Acute myeloid leukemia (AML) is a myeloproliferative neoplasm marked by abnormal clonal expansion of hematopoietic progenitor cells, displaying karyotypic aberrations and genetic mutations as prognostic indicators. The World Health Organization (WHO) and the European LeukemiaNet guidelines categorize BCR::ABL1 p190+ AML as high risk.
Flávia Melo Cunha DE Pinho Pessoa and the team aimed to explore the identification of the increased incidence of BCR::ABL1 p190+ in patients (pts) with AML.
They performed an inclusive analysis of 96 pts with AML stratified according to WHO guidelines. Patients underwent screening for genetic abnormalities, including BCR::ABL1 p190+, PML::RARA, RUNX1::RUNX1T1, and CBFB::MYH11, using quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis.
About 38% of the 96 pts with AML studied exhibited BCR::ABL1 p190+, surpassing anticipated global rates. Age varied from 19 to 78 years, with no notable laboratory variations observed between BCR::ABL1 p190+ and non-BCR::ABL1 p190+ cases. Overall survival analysis showed no statistically significant differences among the pts (P=0.786).
The study concluded that the analyzed adult AML population exhibited a higher frequency of BCR::ABL1 p190+ detection than reported in global literature. This underscores the necessity for further research to understand the underlying reasons for this higher incidence and to determine optimal treatment strategies.
This study was supported by Brazilian funding agencies: Coordination for the Improvement of Higher Education Personnel (CAPES; to C.B.M), National Council of Technological and Scientific Development (CNPq to M.O.d.M.F, M.E.A.d.M, A.S.K. and C.A.M.-N.), Cearense Foundation of Scientific and Technological Support (FUNCAP; to F.M.C.d.P.P and M.O.d.M.F).
Source: https://pubmed.ncbi.nlm.nih.gov/38936913/
DE Pinho Pessoa FMC, Nogueira BMD, Machado CB, et al. (2024). “Molecular and Clinical Insights in the Increasing Detection of BCR::ABL1 p190+ in Adult Acute Myeloid Leukemia Patients.” In Vivo. 2024 Jul-Aug;38(4):2016-2023. doi: 10.21873/invivo.13659. PMID: 38936913; PMCID: PMC11215616.
